Low in Vitro Antifungal Activity of Tavaborole Against Yeasts and Moulds from Onychomycosis [Susceptibility]

The in vitro activity of tavaborole, a FDA approved antifungal drug, was compared to four antifungal agents against 170 clinical fungal isolates originating from patients with onychomycosis. Tavaborole had low activity against all isolates compared to itraconazole, terbinafine and fluconazole, the principal choices for the treatment of onychomycosis. Thus it appears that tavaborole is not a candidate for the treatment of onychomycosis due to Candida species, Aspergillus species and dermatophytes.

https://ift.tt/2xsnbtx